Normalizovaný smoothness index a parametrický populační RDH index telmisartanu u pacientů s čerstvě zjištěnou hypertenzí a metabolickým syndromem

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English The normalized smoothness index and parametric population RDH index of telmisartane in patients with newly diagnosed hypertension
Authors

ŘIHÁČEK Ivan FRÁŇA Petr SCHWARZ Daniel PLACHÝ Martin SOUČEK Miroslav

Year of publication 2010
Type Article in Periodical
Magazine / Source Vnitř. Lék.
MU Faculty or unit

Faculty of Medicine

Citation
Field Cardiovascular diseases incl. cardiosurgery
Keywords hypertenze; metabolický syndrom; normalizovaný smoothness index; RDH index; telmisartan
Description Ambulatory blood pressure monitoring provides an opportunity to evaluate 24hour efficacy of once daily preparations. Aims of the study: To evaluate 24hour efficacy of telmisartan in patients with newly diagnosed hypertension and metabolic syndrome using the parametric population RDH index and normalized smoothness index. Patient sample and methodology: Thirty newly diagnosed hypertonics with metabolic syndrome, sufficiently responding to blood pressure therapy with telmisartan, assessed using sphygmomanometer. Twenty six men, 4 women, mean age of 44 years, body mass index of 31.4, before and after 1 year of therapy. Blood pressure measured with sphygmomanometer and 24hour ambulatory monitoring (SpaceLabs 90207) according to the criteria of the European Society of Hypertension. Hypertension was defined as sphygmomanometer measured blood pressure values of more or equal to 130 and or 85 mm Hg. Fulfilment of at least 3 criteria of metabolic syndrome according to the definition by The Adult Treatment Panel III. Results: The population normalized smoothness index of telmisartan (plusminus standard error of the mean) of 1.00 plusminus 0.11 for systolic pressure and 0.84 plusminus 0.10 for diastolic pressure. The parametric population RDH index of 24, 24, 0 for systolic pressure and 22, 15, 1 for diastolic pressure. Conclusion: Telmisartan at a mean dose of 60 mg once daily showed an adequate 24hour efficacy in patients with newly diagnosed hypertension and metabolic syndrome responding to treatment, when blood pressure was measured using sphygmomanometer and the effect expressed as the parametric population RDH index and normalized smoothness index based on systolic blood pressure value. We did not prove the full 24hour efficacy when diastolic blood pressure was used to calculate both indexes.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info